- Home
- BATL vs TXMD Comparison
BATL vs TXMD Comparison
Compare BATL & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BATL | TXMD |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 24.4M |
| IPO Year | 2004 | 2012 |
Fundamental Metrics
Financial Performance| Metric | BATL | TXMD |
|---|---|---|
| Price | $1.41 | $2.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.7M | 16.4K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 42.56 | ★ 73.68 |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $166,043,000.00 | $1,761,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $207.00 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $1.00 | $0.99 |
| 52 Week High | $29.70 | $2.95 |
Technical Indicators
Market Signals| Indicator | BATL | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 52.67 |
| Support Level | $1.09 | $1.91 |
| Resistance Level | $1.87 | $2.11 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 24.57 | 60.00 |
Price Performance
Historical ComparisonAbout BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.